Recombinant factor VIIa (NovoSeven RT) use in high risk cardiac surgery

European Journal of Cardio-thoracic Surgery

Volumn 40, Issue 6, 2011, Pages 1314-1319

  Chapman, Alistair J ^a   Blount, Andrew L ^a   Davis, Alan T ^b   Hooker, Robert L ^c,d  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b GRMEP Research Department   (United States)

^c West Michigan Cardiothoracic Surgeons   (United States)

^d SPECTRUM HEALTH   (United States)

Author keywords

Factor VII; Hemorrhage; Mortality; Re exploration; RFVIIa; Thrombo embolic

Indexed keywords

FRESH FROZEN PLASMA; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

AGED; ARTICLE; BLOOD; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CRYOPRECIPITATE; DRUG EFFICACY; DRUG SAFETY; DRUG USE; ERYTHROCYTE CONCENTRATE; FEMALE; HEART SURGERY; HEART VALVE SURGERY; HIGH RISK PATIENT; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; REOPERATION; STROKE; THROMBOCYTE TRANSFUSION; THROMBOEMBOLISM; TREATMENT OUTCOME;

AGED; BLOOD COMPONENT TRANSFUSION; CARDIAC SURGICAL PROCEDURES; COAGULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION; FACTOR VIIA; FEMALE; HEMOSTASIS, SURGICAL; HUMANS; MALE; MIDDLE AGED; POSTOPERATIVE CARE; POSTOPERATIVE HEMORRHAGE; RECOMBINANT PROTEINS; REOPERATION; RETROSPECTIVE STUDIES; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 82655181566     PISSN: 10107940     EISSN: 1873734X     Source Type: Journal    
DOI: 10.1016/j.ejcts.2011.03.048     Document Type: Article

References (20)

1. Belisle S., Hardy J.F. Hemorrhage and the use of blood products after adult cardiac operations: myths and realities. Ann Thorac Surg 1996, 62:1908-1917.
2. Dacey L.J., Munoz J.J., Baribeau Y.R., Johnson E.R., Lahey S.J., Leavitt B.J., Quinn R.D., Nugent W.C., Birkmeyer J.D., O'Connor G.T. Reexploration for hemorrhage following coronary artery bypass grafting: incidence and risk factors. Northern New England Cardiovascular Disease Study Group. Arch Surg 1998, 133:442-447.
3. Moulton M.J., Creswell L.L., Mackey M.E., Cox J.L., Rosenbloom M. Reexploration for bleeding is a risk factor for adverse outcomes after cardiac operations. J Thorac Cardiovasc Surg 1996, 111:1037-1046.
4. Engoren M.C., Habib R.H., Zacharias A., Schwann T.A., Riordan C.J., Durham S.J. Effect of blood transfusion on long-term survival after cardiac operation. Ann Thorac Surg 2002, 74:1180-1186.
5. Moskowitz D.M., McCullough J.N., Shander A., Klein J.J., Bodian C.A., Goldweit R.S., Ergin M.A. The impact of blood conservation on outcomes in cardiac surgery: is it safe and effective?. Ann Thorac Surg 2010, 90:451-458.
6. Hedner U., Kisiel W. Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors. J Clin Invest 1983, 71:1836-1841.
7. Hardy J.F., Belisle S., Van der Linden P. Efficacy and safety of activated recombinant factor VII in cardiac surgical patients. Curr Opin Anaesthesiol 2009, 22:95-99.
8. Kogler V.M., Slobodnjak Z., Samarzija M., Macan J.S., Karadza V., Jakopovic M. Successful use of activated recombinant factor VII in life threatening bleeding after thoracic surgery. Swiss Med Wkly 2007, 137:407-410.
9. Dunkley S., Phillips L., McCall P., Brereton J., Lindeman R., Jankelowitz G., Cameron P. Recombinant activated factor VII in cardiac surgery: experience from the Australian and New Zealand Haemostasis Registry. Ann Thorac Surg 2008, 85:836-844.
10. Karkouti K., Beattie S., Arellano R., Aye T., Bussieres J.S., Callum J.L., Cheng D., Heinrich L., Kent B., Lee T.W., MacAdams C., Mazer C.D., Muirhead B., Rochon A.G., Rubens F.D., Sawchuk C., Wang S., Waters T., Wong B.I., Yau T.M. Comprehensive Canadian review of the off-label use of recombinant activated factor VII in cardiac surgery. Circulation 2008, 118:331-338.
11. Karkouti K., Beattie W.S., Crowther M.A., Callum J.L., Chun R., Fremes S.E., Lemieux J., McAlister V.C., Muirhead B.D., Murkin J.M., Nathan H.J., Wong B.I., Yau T.M., Yeo E.L., Hall R.I. The role of recombinant factor VIIa in on-pump cardiac surgery: proceedings of the Canadian Consensus Conference. Can J Anesth 2007, 54:573-582.
12. Nashef S.A., Roques F., Michel P., Gauducheau E., Lemeshow S., Salamon R. European system for cardiac operative risk evaluation (EuroSCORE). Eur J Cardiothorac Surg 1999, 16:9-13.
13. Hyllner M., Houltz E., Jeppsson A. Recombinant activated factor VII in the management of life-threatening bleeding in cardiac surgery. Eur J Cardiothorac Surg 2005, 28:254-258.
14. Cislaghi F., Condemi A.M., Corona A. Predictors of prolonged mechanical ventilation in a cohort of 5123 cardiac surgical patients. Eur J Anaesthesiol 2009, 26:396-403.
15. Roberts H.R., Douglas 3rd D.M., Hoffman M. Safety profile of recombinant factor VIIa. Semin Hematol 2004, 41:101-108.
16. Warren O., Mandal K., Hadjianastassiou V., Knowlton L., Panesar S., John K., Darzi A., Athanasiou T. Recombinant activated factor VII in cardiac surgery: a systematic review. Ann Thorac Surg 2007, 83:707-714.
17. Bove T., Calabro M.G., Landoni G., Aletti G., Marino G., Crescenzi G., Rosica C., Zangrillo A. The incidence and risk of acute renal failure after cardiac surgery. J Cardiothorac Vasc Anesth 2004, 18:442-445.
18. Toole JM, Haney J, Stroud M, Lazarchick J, Crawford F, Uber W, Ikonomidis J. Administration of recombinant activated factor VII in the intensive care unit after complex cardiovascular surgery: clinical and economic outcomes. American Association for Thoracic Surgery 2010 Annual Meeting.
19. Herwaldt L.A., Swartzendruber S.K., Edmond M.B., Embrey R.P., Wilkerson K.R., Wenzel R.P., Perl T.M. The epidemiology of hemorrhage related to cardiothoracic operations. Infect Control Hosp Epidemiol 1998, 19:9-16.
20. Christensen M.C., Krapf S., Kempel A., von Heymann C. Costs of excessive postoperative hemorrhage in cardiac surgery. J Thorac Cardiovasc Surg 2009, 138:687-693.